Skip to main content

Kyverna Therapeutics, Inc.

corporate_fare Company Profile

Kyverna Therapeutics, Inc.

KYTX·NASDAQ·Life Sciences·CIK 0001994702

We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our lead product candidate is mivocabtagene autoleucel, or miv-cel (also known as KYV-101), an anti-CD19 autologous CAR T with a differentiated CAR construct. We have experience treating more than 100 autoimmune patients with miv-cel, documented through scientific publications of autoimmune case studies, our proprietary dataset from compassionate use, ongoing investigator-initiated trials (IITs) at academic institutions, and early clinical data from our company-sponsored trials. These therapies aim to deeply deplete B cells to achieve durable treatment-free remission. Miv-cel is an autologous, fully human CD19-targeting CAR T-cell product candidate designed for potency and tolerability in autoimmune diseases. The underlying chimeric antigen receptor (CAR) for miv-cel is licensed from the National Institutes of Health (NIH). This CAR includes a fully human scFv domain, a human CD8α hinge and transmembrane domain, a human CD28 costimulatory domain, and a human CD3ζ activation domain. The same underlying CAR in miv-cel completed a 20-patient Phase 1 clinical trial in oncology conducted by the NIH. Results from this trial, published in Nature Medicine, reported similar rates of durable antitumor responses and improved tolerability in adult oncology patients compared to the CAR used to create Yescarta®.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for KYTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for KYTX spans 8-K, 10-Q.

Recent high-impact activity:

  • Kyverna Posts Q3 Loss of $41.9M, Ends Quarter With $170.6M and BLA Filed for Miv-cel
  • Kyverna Completes First-Ever Autoimmune CAR-T BLA Filing, Seeks Priority Review in Stiff Person Syndrome
  • Kyverna's miv-cel Shows Two-Year Disability Benefit in Progressive MS
  • Kyverna Reports Durable One-Year SPS and gMG Data; BLA Filing on Track for Q4 2026
  • Kyverna's Miv-cel Shows Durable One-Year Responses in SPS and gMG, BLA on Track for Q4

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$161.31M
Diluted EPS
-$3.64
Op. Cash Flow
-$153.71M
Free Cash Flow
-$153.72M
Operating Income
-$169.83M
Cash & Equivalents
$124.09M
Debt / Equity
0.00×
Shares Outstanding
60.39M sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-126242

Short Interest & Short Volume

11.60 days to cover

FINRA reported short interest of 9,095,664 shares in KYTX as of the October 30, 2026 settlement, a 4.7% decrease from the prior period — about 11.6 days to cover at its recent average daily volume. On November 20, 2026, 60.6% of KYTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,095,664 shares as of October 30, 2026
Change vs prior period▼ 4.7%
Days to cover11.60 at avg daily volume of 784,251
Daily short volume (FINRA facilities)60.6% of 473,097 shares on November 20, 2026
5-day average short volume53.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$4.18 -1.88% today
52-week range · as of 2026-11-12 $4.18 – $13.67
Market cap
$269.33M
Volume
1.3M (1.6× avg)
3-mo avg 856.7K
Live data · 2026-11-22 11:29 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KYTX - Latest Insights

KYTX
Nov 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.20
Real-time Price: $4.18 info
Change: -$1.02 (-20%) info
Market Cap: $269.326M info
KYTX
Nov 12, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.20
Real-time Price: $4.18 info
Change: -$1.02 (-20%) info
Market Cap: $269.326M info
KYTX
Oct 23, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.43
Real-time Price: $4.18 info
Change: -$1.25 (-23%) info
Market Cap: $269.326M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.05
Real-time Price: $4.18 info
Change: -$2.87 (-41%) info
Market Cap: $269.326M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.19
Real-time Price: $4.18 info
Change: -$3.01 (-42%) info
Market Cap: $269.326M info
KYTX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.02
Real-time Price: $4.18 info
Change: -$3.84 (-48%) info
Market Cap: $269.326M info
KYTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $4.18 info
Change: -$3.84 (-48%) info
Market Cap: $269.326M info
KYTX
Jul 27, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.46
Real-time Price: $4.18 info
Change: -$3.28 (-44%) info
Market Cap: $269.326M info
KYTX
Jul 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.46
Real-time Price: $4.18 info
Change: -$3.28 (-44%) info
Market Cap: $269.326M info
KYTX
Jul 09, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.82
Real-time Price: $4.18 info
Change: -$5.64 (-57%) info
Market Cap: $269.326M info
KYTX
Jun 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.07
Real-time Price: $4.18 info
Change: -$3.89 (-48%) info
Market Cap: $269.326M info
KYTX
Jun 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.10
Real-time Price: $4.18 info
Change: -$3.92 (-48%) info
Market Cap: $269.326M info
KYTX
May 18, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.35
Real-time Price: $4.18 info
Change: -$5.17 (-55%) info
Market Cap: $269.326M info
KYTX
May 12, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.34
Real-time Price: $4.18 info
Change: -$6.16 (-60%) info
Market Cap: $269.326M info
KYTX
May 12, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.30
Real-time Price: $4.18 info
Change: -$6.12 (-59%) info
Market Cap: $269.326M info
KYTX
May 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.35
Real-time Price: $4.18 info
Change: -$6.17 (-60%) info
Market Cap: $269.326M info
KYTX
May 04, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.81
Real-time Price: $4.18 info
Change: -$4.63 (-53%) info
Market Cap: $269.326M info
KYTX
Apr 22, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.90
Real-time Price: $4.18 info
Change: -$6.72 (-62%) info
Market Cap: $269.326M info
KYTX
Apr 21, 2026, 6:45 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $10.18
Real-time Price: $4.18 info
Change: -$6.00 (-59%) info
Market Cap: $269.326M info
KYTX
Apr 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.94
Real-time Price: $4.18 info
Change: -$5.76 (-58%) info
Market Cap: $269.326M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets